Ironwood Pharmaceuticals Price Target Increased to $15.00 by Analysts at Leerink Swann (IRWD)
Analysts at Leerink Swann increased their price objective on shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from $12.15 to $15.00 in a research report issued to clients and investors on Monday. Leerink Swann’s target price would indicate a potential upside of 10.13% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Ironwood Pharmaceuticals in a research note on Wednesday, April 30th. They now have a $22.00 price target on the stock. Separately, analysts at Cantor Fitzgerald reiterated a “hold” rating on shares of Ironwood Pharmaceuticals in a research note on Wednesday, April 30th. They now have a $11.00 price target on the stock. Finally, analysts at Aegis reiterated a “positive” rating on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 29th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $13.59.
Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at 13.62 on Monday. Ironwood Pharmaceuticals has a one year low of $8.95 and a one year high of $15.47. The stock has a 50-day moving average of $11.65 and a 200-day moving average of $12.11. The company’s market cap is $1.880 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Tuesday, April 29th. The company reported ($0.38) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.44) by $0.06. The company had revenue of $14.60 million for the quarter, compared to the consensus estimate of $8.52 million. During the same quarter in the prior year, the company posted ($0.87) earnings per share. The company’s quarterly revenue was up 342.4% on a year-over-year basis. Analysts expect that Ironwood Pharmaceuticals will post $-1.31 EPS for the current fiscal year.
Ironwood Pharmaceuticals, Inc is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.